Abstract | BACKGROUND:
SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program ( PPTP). PROCEDURES:
SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. RESULTS: CONCLUSIONS:
SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.
|
Authors | E Anders Kolb, Richard Gorlick, Peter J Houghton, Christopher L Morton, Richard Lock, Hernan Carol, C Patrick Reynolds, John M Maris, Stephen T Keir, Catherine A Billups, Malcolm A Smith |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 50
Issue 6
Pg. 1190-7
(Jun 2008)
ISSN: 1545-5017 [Electronic] United States |
PMID | 18260118
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | (c) 2007 Wiley-Liss, Inc. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Receptor, IGF Type 1
- robatumumab
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(therapeutic use)
- Cell Line, Tumor
(drug effects, pathology)
- Cell Proliferation
(drug effects)
- Cells, Cultured
- Child
- Female
- Humans
- Mice
- Mice, Inbred Strains
- Receptor, IGF Type 1
(immunology)
- Xenograft Model Antitumor Assays
|